Antidotes for patients taking novel oral anti-coagulants  

作　　者：Stefanie W Yip Yiu Che Chan 

机构地区：[1]Division of Vascular & Endovascular Surgery,Department of Surgery K 14 South,Queen Mary Hospital Pokfulam,University of Hong Kong Medical Centre

出　　处：《World Journal of Emergency Medicine》2015年第4期311-312,共2页世界急诊医学杂志（英文）

摘　　要：Dear Sir：Novel oral anti-coagulants [NOACs： dabigatran （Pradaxa , Boehringer Ingelheim, Germany）, rivaroxaban （Xarelto , Bayer, Germany）, apixaban （Eliquis , Bristol-Myers Squibb, USA）, edoxaban （Savaysa , Daiichi-Sankyo, Japan）] are used more often for the prevention of systemic embolism in atrial fibrillation and for the treatment of venous thromboembolism. Unlike warfarin, NOACs have more predictable pharmacokinetics, fewer drug interactions, shorter half-lives, and quicker onset of action.[1] They do not require frequent laboratory monitoring, but there is a lack of validated reversal strategies for these agents in cases of emergency surgery, life-threatening bleeding, and overdose.[2] Elderly patients with impaired renal function are especially vulnerable.

关 键 词：医患关系 临床 医院管理 

分 类 号：R973[医药卫生—药品]